Eli Lilly and Company (LLY) Form 4 Filings

Eli Lilly & Co. President, Chair, and CEO David A. Ricks reported a gift disposition of 23,538 common shares on November 3, 2026; his direct holdings afterward were 555,278 shares. No Rule 10b5-1 plan is reported. The November 3 holdings also list 4,574 shares in his 2025 GRAT, 49,127 in his 2022 GRAT, 300 in a trust, 68,656 in his SLAT, and 7,338 in a 401(k). Ricks disclaims beneficial ownership of securities in the GRAT, trust, and SLAT entries except to the extent of his pecuniary interest.

Eli Lilly & Co. EVP, CS&PO & Pres. LRL Daniel Skovronsky reported a bona fide gift disposition of 119 common shares on November 2, 2026; no Rule 10b5-1 plan is reported. His reported direct holdings after the transfer were 159,953 shares. The report also lists indirect holdings as of November 2, 2026: 72,359 shares by trust, 547 by spouse, and 2,710 by spouse’s SLAT. A footnote attached to those indirect holdings says he disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Eli Lilly & Co. (LLY) reported an indirect sale by the spouse of Anat Hakim, its EVP, GC & Secretary: 5,000 common shares at $1,402.52 per share on November 2, 2026, under a Rule 10b5-1 trading plan adopted February 10, 2026. The reported spouse-held balance after the sale was 4,137 shares. Separate entries list 25,725 directly held shares, reflecting a net transfer of 2,738 shares from the spouse, and 15,700 shares held indirectly by Anat Hakim SLAT.

Eli Lilly EVP & CFO Lucas Montarce converted 1,610 restricted stock units into 1,610 common shares on November 1, 2026. Each unit represents a contingent right to receive one common share, and the reported restricted-stock-unit position was 0 after conversion. On the same date, 678 common shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $1,417.54 per share.

Eli Lilly & Co. EVP & President, Manufacturing Operations Edgardo Hernandez exercised 2,530 restricted stock units on November 1, 2026, acquiring 2,530 common shares; each unit represents a contingent right to receive one common share. On the same date, 1,122.902 common shares were delivered or withheld for payment of exercise price or tax liability. The restricted-stock-unit position following the transaction was zero. Hernandez also reported 874.6 common shares held indirectly through a 401(k) as of November 1, 2026.

Eli Lilly & Co reported that Eric Dozier, EVP, Chief People Officer, exercised 2,300 restricted stock units on November 1, 2026, acquiring 2,300 common shares; each unit represents a contingent right to one common share. He also delivered or had withheld 1,019 common shares for payment of exercise price or tax liability. The derivative position following the transaction was 0 restricted stock units; an indirect 401(k) holding lists 414 common shares as of November 1, 2026. No Rule 10b5-1 plan is reported.

Eli Lilly & Co. EVP & President, Card Met Hlth Kenneth L. Custer exercised 3,220 restricted stock units on November 1, 2026, and acquired 3,220 shares of common stock. On the same date, 1,425 shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $1,417.54 per share. The reported restricted stock unit position following the exercise was 0.

At Eli Lilly & Co., Adrienne S. Brown, EVP, President LLY Imm, exercised 2,530 restricted stock units into 2,530 common shares on November 1, 2026. On that date, 1,099 common shares were delivered or withheld for payment of exercise price or tax liability; the reported price was $1,417.54 per share. No Rule 10b5-1 plan is reported for the transaction.

Eli Lilly & Co. director Gabrielle Sulzberger acquired 3.9976 shares of common stock on October 19, 2026, at a reported price of $1,240.34 per share. At her election, the shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following her separation from service. Her reported direct holdings after the transaction were 3,016.4449 shares.

Eli Lilly & Co. director Juan R. Luciano reported an award acquisition of 12.8325 shares of common stock on October 19, 2026. The transaction lists a per-share price of $1,240.3400. The shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following his separation from service. His reported direct position after the transaction was 16,969.6463 shares.

Eli Lilly & Co. director J. Erik Fyrwald reported acquiring 8 shares of common stock on October 19, 2026, at a reported $1,240.34 per share. At his election, the acquired shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares following his separation from service. His reported direct position following the transaction was 75,544 shares.

Eli Lilly & Co. director Ralph Alvarez acquired 10 shares of common stock on October 19, 2026, at a reported price of $1,240.3400 per share. The shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock following his separation from service. His direct common-stock holdings following the acquisition were 55,848 shares. A separate reported holding lists 758 common shares indirectly held by a trust; Alvarez disclaims beneficial ownership except to the extent of his pecuniary interest.

ELI LILLY & Co (LLY) reported that director Gabrielle Sulzberger acquired a small additional position in common stock through a compensation-related award. On September 21, 2026, she received 4.2565 shares credited at $1,164.89 per share, bringing her directly held total to 3,012.4473 shares. Per her election, this award has been deferred into stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after her separation from service.

ELI LILLY & Co (LLY) director Juan R. Luciano reported an acquisition of 13.6637 shares of common stock on September 21, 2026, as a grant/award valued at $1,164.89 per share. Under the Lilly Directors' Deferral Plan, these shares are deferred as stock units and will be settled in common stock after his separation from service, bringing his directly held equivalent position to 16,956.8138 shares.

ELI LILLY & Co (LLY) reported that director J. Erik Fyrwald acquired an award of 8.513 shares of common stock on September 21, 2026, valued at $1,164.89 per share. Following this grant, Fyrwald’s directly held position is 75,536.1308 shares, which have been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service.

ELI LILLY & Co (symbol: LLY) is the issuer of record for a Form 4 filing submitted to the SEC. Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co (LLY) director Ralph Alvarez reported an automatic grant of 10.6591 shares of common stock on September 21, 2026, valued at $1,164.89 per share. At Mr. Alvarez’s election, this award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, he holds 55,838.2192 shares directly and 758 shares indirectly through a trust, for which he disclaims beneficial ownership except for his pecuniary interest.

ELI LILLY & Co (LLY) executive Melissa Seymour, EVP, Global Quality, reported two bona fide gifts of Eli Lilly common stock. She gifted 12 shares on September 9, 2026, and 17 shares on September 22, 2025. The 2025 gift was disclosed as having been inadvertently not reported at the time. No Rule 10b5-1 trading plan is reported.

ELI LILLY & Co (LLY) executive Edgardo Hernandez, EVP & President, Manufacturing Operations, reported a bona fide gift of 13 shares of common stock on September 2, 2026. After this gift, he held 46,082.717 shares directly and 874.220 shares indirectly through a 401(k) account.

No transactions were reported under a Rule 10b5-1 trading plan.

ELI LILLY & Co (LLY) reported that executive vice president and chief people officer Eric Dozier made a bona fide gift of 216 shares of common stock on September 2, 2026. After this gift, he held 14,239.212 shares directly and 413.44 shares indirectly through a 401(k) plan. No transactions were reported under a Rule 10b5-1 trading plan.

ELI LILLY & Co (LLY) director Gabrielle Sulzberger reported an acquisition of 4.1908 shares of common stock on August 17, 2026, as a grant/award. According to the director deferral plan, the value was deferred as stock units in lieu of cash compensation and will be settled in shares after her separation from service, bringing her directly held equivalent share balance to 3003.9096 shares.

ELI LILLY & Co (LLY) director Juan R. Luciano reported the acquisition of 13.4527 shares of common stock on 2026-08-17 through a grant/award. According to the deferral election, these shares have been credited as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in common stock after his separation from service. Following this award, his directly owned position is reported as 16,918.0448 shares.

ELI LILLY & Co (symbol: LLY) is the issuer of record for a Form 4 filing submitted to the SEC.

ELI LILLY & Co (LLY) director Ralph Alvarez reported an acquisition of common stock as compensation. On 2026-08-17, he received 10.4945 shares valued at $1183.16 per share, granted as deferred stock units under the Lilly Directors' Deferral Plan, to be settled in shares after he leaves board service. Following this, he holds 55,744.788 shares directly and 758 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest.

ELI LILLY & Co (LLY) executive Patrik Jonsson, EVP & President, LLY International, reported selling 6,500 shares of common stock on 2026-08-17 at $1,175.10 per share in an open-market or private transaction. After this sale, he directly holds 54,146.62 shares and has an additional 632.40 shares held indirectly through a 401(k) plan. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 17, 2026.

ELI LILLY & Co officer Donald A. Zakrowski, SVP, Finance, & CAO, reported selling 2,000 shares of common stock on 2026-08-10 at an average price of $1,185.01 per share in an open-market transaction. After this sale, he held 1,525.89 shares directly and 1,734.73 shares indirectly through a 401(k). The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.

ELI LILLY & Co executive Anat Hakim, EVP, GC & Secretary, reported a sale of 5,000 shares of common stock on August 7, 2026 at $1,190.00 per share. The shares were held indirectly through her spouse, and she disclaims beneficial ownership except to the extent of her pecuniary interest. The transaction was effected under a Rule 10b5-1 trading plan adopted on February 10, 2026. After the sale, 11,875 shares remained held indirectly by her spouse, 22,987.024 shares were held directly, and 15,700 shares were held indirectly through the Anat Hakim SLAT.

ELI LILLY & Co executive Melissa Seymour, EVP Global Quality, exercised 981 restricted stock units into an equal number of common shares on August 1, 2026. To satisfy exercise price or tax obligations, 438.707 shares were withheld at $1,148.8400 per share, and 952 RSUs remain scheduled to vest on August 1, 2027.

ELI LILLY & Co director Gabrielle Sulzberger reported a grant/award acquisition of 4.3232 shares of common stock on July 20, 2026 at $1,146.90 per share. At her election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after her separation from service. Following this award, she directly holds 2,999.7188 shares of Eli Lilly common stock.

LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co director Juan R Luciano received a grant of 13.878 shares of common stock on 2026-07-20 at $1,146.9000 per share. These shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after his separation from service. Following this award, he directly holds 16,904.5921 shares.

Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.

Eli Lilly director J Erik Fyrwald elected to receive 8.6465 shares’ worth of common stock on July 20, 2026 as deferred stock units in lieu of cash director compensation at $1,146.90 per share, bringing his direct holdings to 75,409.7433 shares, to be settled after his separation from service.

Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co director Ralph Alvarez received an award of 10.8263 common shares on 2026-07-20, valued at $1146.9000 per share. At his election, the award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after separation from service. Following this grant, he holds 55734.2935 shares directly and 758.0000 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest. The report indicates the transaction was not made under a Rule 10b5-1 trading plan.

ELI LILLY & Co director Gabrielle Sulzberger received a stock-based compensation award rather than making an open-market trade. She acquired 4.3904 shares of common stock on an award basis at $1,129.35 per share, bringing her direct holdings to 2,995.3956 shares.

According to the company’s directors’ deferral program, she elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan. These units will be settled in shares of common stock after she separates from board service, so this filing reflects a deferred equity award, not a cash salary payment or market purchase.

ELI LILLY & Co director Juan R. Luciano received a grant of 14.0937 shares of common stock at $1,129.35 per share. At his election, this award has been deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following this compensation-related acquisition, his direct holdings total 16,890.7141 shares of common stock.

Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co director J Erik Fyrwald received a grant of 8.7809 shares of common stock equivalent on a deferred basis. The award was priced at $1,129.35 per share and was taken in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. After this grant, Fyrwald holds a total of 75,401.0968 shares of Lilly common stock directly, including these deferred stock units, which will be settled in shares after his separation from service.

ELI LILLY & Co director Ralph Alvarez reported a compensation-related stock award, increasing his direct holdings. On June 15, 2026, he acquired 10.9945 shares of common stock at $1,129.35 per share, characterized as a grant or award rather than an open-market purchase.

According to the footnotes, these shares were deferred as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation and will be settled in common stock after he leaves the board. Following this award, Alvarez directly holds 55,723.4672 shares of common stock and indirectly holds 758 shares through a trust, where he disclaims beneficial ownership beyond his pecuniary interest.

ELI LILLY & Co executive Ilya Yuffa reported an insider sale of company stock. On June 10, 2026, Yuffa, EVP & President, LLY USA & Global Capabilities, completed an open-market sale of 2,500 shares of Eli Lilly common stock at an average price of $1,150.77 per share.

The transaction was carried out under a Rule 10b5-1 trading plan that Yuffa adopted on February 13, 2026, indicating it was pre-arranged. Following this sale, he directly holds 29,804.111 shares of Eli Lilly common stock.

ELI LILLY & Co director Gabrielle Sulzberger received a stock award equivalent to 5.018 shares of common stock, valued at $988.09 per share. The award was not a market purchase but a grant reported as an acquisition.

According to the disclosure, Sulzberger elected to defer this compensation into stock units under the Lilly Directors' Deferral Plan, instead of taking cash. These stock units will be settled in shares of common stock after her separation from service. Following this grant, her directly held and reported common stock interest totals 2,986.617 shares.

LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.

ELI LILLY & Co director Juan R. Luciano received an equity award of 16.109 shares of common stock on May 18, 2026, valued at $988.09 per share. According to the filing, he elected to defer this grant into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this award, he directly holds 16,850.832 shares of Lilly common stock.

ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award, not an open-market trade. He acquired 10.036 shares of common stock on May 18, 2026 at a reference price of $988.09 per share through a grant.

Under the Lilly Directors' Deferral Plan, he elected to defer this award as stock units, to be settled in common shares after his separation from service. Following this grant, his direct holdings increased to 75,279.592 shares of Lilly common stock.

ELI LILLY & Co director Ralph Alvarez reported an acquisition of 12.566 shares of common stock at $988.0900 per share as a grant or award. At his election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after his separation from service. Following the transaction, he directly holds 55,627.279 shares of common stock and indirectly holds 758 shares by trust, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Lilly Endowment Inc, a former 10% shareholder of ELI LILLY & Co, sold a total of 15,828 shares of common stock in open-market transactions. The sales occurred at weighted average prices of about $995.23 and $996.18 per share, with execution prices ranging from $995.00 to $996.46. After these transactions, Lilly Endowment continues to hold about 91,881,150 shares of Eli Lilly common stock.

Eli Lilly & Co director Gabrielle Sulzberger received a compensation-related stock grant rather than buying shares on the market. On this award, she acquired 5.39 shares of common stock at $919.90 per share, bringing her direct holdings to 2,981.599 shares.

According to the disclosure, she elected to defer this grant into stock units under the Lilly Directors' Deferral Plan. These units will be settled in Eli Lilly common stock after she separates from board service, turning current cash compensation into future share-based value.

ELI LILLY & Co director Juan R. Luciano received a small stock grant. He acquired 17.3030 shares of common stock as a grant or award at a reported price of $919.9000 per share. After this transaction, he directly holds a total of 16,834.7230 Eli Lilly common shares.

ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade. He acquired 10.78 shares of common stock at $919.90 per share through a grant classified as a “grant, award, or other acquisition.”

According to the footnote, he elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, his direct holdings total 75,269.556 Lilly common shares.

ELI LILLY & Co director Ralph Alvarez increased his equity-based compensation exposure through a deferred stock award. He acquired 13.498 shares of common stock equivalent as a grant or award at $919.90 per share, electing to defer cash compensation into stock units under the Lilly Directors' Deferral Plan.

After this award, his directly held common stock totaled 55,614.713 shares, with an additional 758 shares held indirectly by a trust. The deferred stock units will be settled in shares of common stock following his separation from service, and he disclaims beneficial ownership except to the extent of his pecuniary interest.

ELI LILLY & Co director Gabrielle Sulzberger reported a small stock-based compensation grant. She acquired 5.013 shares of common stock on March 16, 2026 at a price of $989.12 per share through a grant or award rather than an open-market purchase.

According to the disclosure, she elected to defer these shares as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock after she separates from service. Following this grant, she directly holds a total of 2,976.209 shares of Eli Lilly common stock.

Eli Lilly & Co director Juan R. Luciano received a stock-based compensation award rather than cash fees. On 2026-03-16, he acquired 16.092 shares of common stock at $989.12 per share as a grant or award. Following this transaction, he directly holds 16,817.420 shares of Eli Lilly common stock.

According to the company’s directors’ deferral plan, these shares have been deferred as stock units in lieu of cash compensation and will be settled in actual shares of common stock after Luciano separates from service as a director.

ELI LILLY & Co director J. Erik Fyrwald reported a small stock-based compensation grant. He acquired 10.026 shares of common stock valued at $989.12 per share, increasing his direct holdings to 75,258.776 shares.

The filing notes he elected to defer this award into stock units under the Lilly Directors' Deferral Plan, to be settled in Eli Lilly common stock after he separates from board service. This is a routine director compensation transaction rather than an open-market purchase or sale.

Eli Lilly & Co director Ralph Alvarez reported an automatic stock-based compensation grant. On March 16, 2026, he acquired 12.553 shares of common stock at $989.12 per share as a grant or award, increasing his directly held position to 55,601.215 shares.

According to the company’s directors’ deferral plan, Alvarez elected to defer this award as stock units instead of cash compensation, to be settled in common shares after he leaves the board. The filing also shows an indirect holding of 758 shares held by a trust, for which he disclaims beneficial ownership beyond his economic interest.